Table 1.
Baseline clinical data of all studied SLE children and controls
| Parameter | SLE patients (20) | Control (20) | p |
|---|---|---|---|
| Age (years) | |||
| Range | 7–16 | 7–16 | NS |
| Mean±SD | 9.4±3.7 | 9.0±4.5 | NS |
| Disease duration (years) | 4.5±2.8 | – | – |
| Male/female | 2/18 | 2/18 | NS |
| SLEDAI | |||
| Range | 2–31 | – | – |
| Mean±SD | 11.3±7.6 | – | – |
| ACR criteria of SLE: no. (%) | |||
| Malar rash | 7 (35%) | – | – |
| Discoid rash | 2 (10%) | – | – |
| Photosensitivity | 2 (10%) | – | – |
| Oral ulcers | 1 (5%) | – | – |
| Arthritis | 11 (55%) | – | – |
| Serositis | 5 (25%) | – | – |
| Renal disorders | 8 (40%) | – | – |
| Neuropsychiatric disorders | 9 (45%) | – | – |
| Hematological disease | 13 (65%) | – | – |
| Positive antinuclear antibodies | 10 (50%) | – | – |
| Positive anti-dsDNA antibodies | 10 (50%) | – | – |
| Other clinical data | |||
| Fatigue | 16 (80%) | – | – |
| Pulmonary disorders | 3 (15%) | – | – |
ACR, American College of Rheumatology; NS, not significant; SD, standard deviation; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.